Pharmacology of amygdalin (laetrile) in cancer patients

Cancer Chemother Pharmacol. 1981;6(1):51-7. doi: 10.1007/BF00253010.

Abstract

Plasma and urine concentrations of amygdalin, whole-blood concentrations of cyanide, and thiocyanate concentrations in serum and urine were determined in cancer patients following intravenous (4.5 g/m2) and oral (500-mg tablet) administration of amygdalin. To measure low plasma concentrations of amygdalin following oral administration a GC/MS assay was developed. Following intravenous administration, concentrations of parent drug as high as 1,401 microgram/ml were observed, with no increase in plasma concentrations of cyanide or serum concentrations of thiocyanate. Plasma elimination of amygdalin was best described by a two-compartment open model with a mean distributive phase half-life of 6.2 min, mean elimination phase half-life of 120.3 min, and mean clearance of 99.3 ml/min. Following oral administration of amygdalin, plasma concentrations were much lower, with peak values of less than 525 ng/ml. Cyanide concentrations increased to values as high as 2.1 microgram/ml whole blood. Thiocyanate concentrations did not increase for several days, plateauing at values as high as 38 microgram/ml serum. Ingestion of almonds by two patients taking oral amygdalin increased cyanide concentrations compared with values obtained after oral amygdalin alone.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Administration, Oral
  • Amygdalin / administration & dosage
  • Amygdalin / metabolism*
  • Cyanides / metabolism
  • Gas Chromatography-Mass Spectrometry
  • Humans
  • Injections, Intravenous
  • Neoplasms / metabolism*
  • Thiocyanates / metabolism

Substances

  • Cyanides
  • Thiocyanates
  • Amygdalin